SPOTLIGHT -
Painting Pharma Green
New marketing agency helps pharma companies clean up their act
Amgen Under the Knife
California biotech adds to industry?s pink-slip count
Slapped with a Black Box
Diabetes drugs to feature warnings for heart failure
Nielsen Creates Pharma Division
NielsenHealth rises from the ashes of failed deal with IMS Health
Marketing Where the Kids Are
Pharma surfaces on MySpace
J&J to Cut Costs and Jobs
Company follows industry's job-slashing trend
Pfizer Fires Three?
Pharma giant's house gets a little cleaner after whistle-blower's accusations
Avandia Survives
Advisory committees recommend that the popular diabetes drug remain on the market--but with new warnings
Zelnorm Returns--Sort Of
Novartis' Zelnorm is back, but only through a restricted-access program.
Anti-Obesity Drugs Struggle In Growing Market
A new study says obesity is like a social virus, so why is the obesity-drug market just sitting there?
CE: Cardiovascular disease and cancer in women
August 2008 CE
Severin' Ties
Severin Schwan takes over at Roche
Contamination Alert
Tainted batches of Viracept pulled from European shelves.
Forecasting DTC's Future
Spending expected to increase mildly in the short term
The Oprah Moment
In the wake of a high-profile death from counterfeit drugs, the industry reacts
Novartis to Intercell: "Gimme All Your Vax."
But is the pharma-biotech vaccine deal a prelude to a takeover?
Pharma Skinny In Briefs
It was a short, sweaty week complete with fireworks....
Roche to Ventana: "Let's Make A Deal"
...And the spurned suitor won't take "No" for an answer
Oh Man, Avandia
All hell broke loose on May 21 when the New England Journal of Medicine released Cleveland Clinic cardiologist Dr. Steven Nissen's meta-analysis of 42 studies of Avandia, showing a 43 percent increased risk of heart attack.
Post-regulatory
The Acomplia story isn't ending. It's just beginning. Get ready to see what happens when a much-desired drug is marketed by people accountable to no one.
Merck's Not-So-New Marketing Model
Or: No news is good news--for everyone but us reporters
Marketing Blues for SSRIs?
Blockbuster antidepressants linked to bone loss in seniors
Testing, Testing, H-I-V
Catching up with the first ouchless fast test on National HIV Testing Day
CE: Common issues in women's health
July 2007 CE
Glaxo Gives High-Five to Cancer Market
Big crop of oncology drugs is the fruit of Garnier's excellent restructuring
Abbott's Risky Strategy In AIDS-drug Struggle
New lawsuit against activists shows CEO Miles White maverick MO
Global Access for Pfizer's New HIV Drug
Maraviroc's promise shows the value of expanded-access programs
Allez, Alli, But Acomplia, We Hardly Knew Ye
FDA fears may prevent a showdown between two weight-loss heavyweights.
What's Hot and What's Not in Oncology
The take-home from the American Society of Clinical Oncology.
Most Post-Marketing Studies Deliver ''Duh'' Data
But no news is good news for a drug?s safety profile, a new study says
